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Considering the involvement of a redox-regulatory pathway in the expression of human papillomaviruses
(HPVs), HPV type 16 (HPV-16)-immortalized human keratinocytes were treated with the antioxidant pyrro-
lidine-dithiocarbamate (PDTC). PDTC induces elevated binding of the transcription factor AP-1 to its cognate
recognition site within the viral regulatory region. Despite of increased AP-1 binding, normally indispensable
for efficient HPV-16 transcription, viral gene expression was selectively suppressed at the level of initiation of
transcription. Electrophoretic mobility supershift assays showed that the composition of the AP-1 complex,
predominantly consisting of Jun homodimers in untreated cells, was altered. Irrespective of enhanced c-fos
expression, c-jun was phosphorylated and became primarily heterodimerized with fra-1, which was also induced
after PDTC incubation. Additionally, there was also an increased complex formation between c-jun and junB.
Because both fra-1 and junB overexpression negatively interferes with c-jun/c-fos trans-activation of AP-1-
responsive genes, our results suggest that the observed block in viral transcription is mainly the consequence
of an antioxidant-induced reconstitution of the AP-1 transcription complex. Since expression of the c-jun/c-fos
gene family is tightly regulated during cellular differentiation, defined reorganization of a central viral
transcription factor may represent a novel mechanism controlling the transcription of pathogenic HPVs during
keratinocyte differentiation and in the progression to cervical cancer.
Specific types of human papillomaviruses (HPVs) such as
HPV type 16 (HPV-16) (18) and HPV-18 (6) are etiologically
involved in the development of cervical cancer (84, 86). The
oncogenic potential of the virus can be attributed to the E6 and
E7 open reading frames (46), whose gene products can func-
tionally interfere with cell cycle control in part by interacting
with presumptive tumor suppressor proteins such as p53 (82)
or the retinoblastoma protein (Rb) (20).
Although E6 and E7 themselves possess intrinsic trans-acti-
vation capacity on their homologous promoters (14, 52), con-
stitutive expression of E6 or E7 in immortalized or malignantly
transformed human keratinocytes is mainly dependent on the
availability of a defined set of transcription factors derived
from the infected host cell. AP-1, for example, normally con-
sisting of a heterodimer between c-Fos and c-Jun (for a review,
see reference 4), seems to play a central role in transcriptional
regulation of viral oncogene expression, since point mutations
of the corresponding consensus sequences within the upstream
regulatory region (URR) of HPV-16 or HPV-18 almost com-
pletely abolish the expression of URR-driven reporter plas-
mids in transient transfection assays (7, 12, 77).
Recent studies have shown that trans-activation and the
DNA-binding affinity of AP-1 (1, 44) as well as that of other
transcription factors such as NF-kB (65, 78) or p53 (29) can be
modulated not only via posttranslational modifications such as
phosphorylation or dephosphorylation (for a review, see ref-
erence 31) but also by alterations of the intracellular redox
status. This can be achieved by certain cytokines, which are
able to induce a prooxidant state within the cell by generating
reactive oxygen intermediates (ROIs) (26, 44). Following the
binding to their respective receptors on the cell surface, intra-
cellular ROIs in turn act as second messengers to transduce
the signal into the nucleus (65). A paradigm for such a trans-
duction-activation mechanism is the transcription factor NF-
kB. Reactive oxygen triggers the release of the cytoplasmic
inhibitory component (IkB) of NF-kB, leading to nuclear
translocation of the p50 and p65 subunits and subsequently to
the activation of a whole set of NF-kB-responsive effector
genes (65, 68).
Similar prooxidant conditions can also be generated either
by exposing cells directly to hydrogen peroxide (40) or by
genotoxic stress after UV irradiation (60), leading in both cases
to the activation of AP-1 (74) and NF-kB (44). While such
intracellular redox changes are normally counterbalanced by
antioxidant enzymes like Cu-Zn-superoxide dismutases (48) or
oxidoreductases such as thioredoxin (30, 43), it is also possible
to interfere directly with the redox regulation of a given gene
by treating the cells with antioxidative drugs such as pyrroli-
dine-dithiocarbamate (PDTC) (67).
In a previous study, we showed that tumor necrosis factor
alpha-induced transcription of a chemokine gene encoding
monocyte chemoattractant protein 1 (MCP-1) could be com-
pletely abrogated when nonmalignant HPV-positive cells were
incubated with PDTC prior to cytokine addition (57). Consis-
tent with the aforementioned model of redox modulation of
specific genes, detailed promoter analysis has revealed that
NF-kB and AP-1 are indeed the predominant transcription
factors involved in the regulation of this particular chemokine
(70, 80).
Since AP-1 is also a central transcription factor for efficient
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gene expression of HPVs (12, 49), we investigated the effect
PDTC on the transcription of HPV-16 in human keratinocytes.
In the present study, we show that PDTC increases AP-1 bind-
ing affinity to the corresponding binding site within the viral
regulatory region. However, despite the fact that AP-1 is re-
quired for efficient HPV-16/18 transcription (7, 12, 77), the
observed enhanced AP-1 binding is accompanied by a selective
suppression of viral gene expression on the level of initiation of
transcription. Although the antioxidant elicits up-regulation of
c-Fos and c-Jun, both at the transcriptional level and at the
protein level, band-shift assays in combination with specific
antibodies revealed that only c-Jun but not c-Fos becomes a
major component in the AP-1 complex. While JunB is also
slightly elevated, JunD binding is not affected.
PDTC not only induces c-Jun overexpression but also causes
its phosphorylation. Most notable is the observation that in-
stead of c-Fos, another member of the Fos family, Fra-1, was
found to be the major binding partner of c-Jun and JunB after
PDTC application. Since overexpression of Fra-1 has an inhib-
itory effect on the trans-activating efficiency of prototype AP-1
(75), known to be obligatory for HPV16/18 gene expression (7,
12, 77), our results suggest that the suppression of viral tran-
scription is mainly a consequence of a PDTC-induced alter-
ation in the heterodimerization pattern of AP-1.
MATERIALS AND METHODS
Cell culture. HPV-16-positive human keratinocytes (19), the HPV-18-positive
cervical carcinoma cell line HeLa, and the HPV-negative cervical carcinoma cell
line C33a were maintained in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum and 1% penicillin-streptomycin. PDTC was
obtained from Sigma Chemical and was freshly dissolved in medium immediately
before use. Actinomycin D and cycloheximide (Sigma) were stored as stock
solutions at 2208C.
RNA analysis. Cellular RNA was extracted according to the guanidinium-
thiocyanate method (9). Between 2.5 and 5 mg of total RNA was separated on
1% agarose gels in the presence of ethidium bromide under nondenaturating
conditions (33) and transferred to GeneScreen Plus membranes.
Nuclear run-on assay. Cells were washed twice with ice-cold phosphate-buff-
ered saline, scraped from the plates with a rubber policeman, and lysed in 5 ml
of 10 mM Tris-HCl (pH 7.4)–10 mM NaCl–2 mM MgCl2–0.5 mM phenylmeth-
ylsulfonyl fluoride–5 mM dithiothreitol (DTT)–0.5% Nonidet P-40 (Boehringer,
Mannheim, Germany). After cytoplasm removal, the nuclei were resuspended in
storage buffer (50 mM Tris-HCl [pH 7.4], 5 mM MgCl2, 0.1 mM EDTA, 5 mM
DTT, 40% [vol/vol] glycerol) and frozen in liquid nitrogen (55). The nuclear
run-on assay was performed as described previously (39), with the only modifi-
cation that the [32P]UTP-labeled RNAs were recovered by the method of Chom-
czynski and Sacchi (9). Equal amounts of radiolabeled RNA were hybridized to
plasmid and total cell DNA immobilized on small nitrocellulose strips as indi-
cated in the figure legends.
Plasmids for transient transfection assays. pH16CAT and pH18CAT harbor
the complete URRs of HPV-16 and HPV-18 cloned in pBLCAT3, a chloram-
phenical acetyltransferase (CAT) construct lacking any eukaryotic regulatory
signals. The plasmids were kindly provided by A. Alonso and T. Bauknecht
(Deutsches Krebsforschungszentrum, Heidelberg, Germany). pBLCAT2 consists
of the thymidine kinase (tk) promoter of herpes simplex virus (HSV) cloned in
pBLCAT3 (41). pSVCAT2 carries the complete promoter/enhancer region of
simian virus 40 in front of the CAT gene (27). p3xNF-kB-CAT (64) and p3xAP-
CAT (3) represent reporter plasmids where either three NF-kB consensus se-
quences or three 12-O-tetradecanoylphorbol-13-acetate-responsive elements
(TREs) were cloned in front of the tk promoter of HSV. Both constructs were
kindly made available by W. Dro¨ge and P. Angel (Deutsches Krebsforschungs-
zentrum). pTopoI-CAT harbors the regulatory region of the human topoisom-
erase I gene (35). pRSV-luc contains a luciferase gene under the control of the
Rous sarcoma virus (RSV) long terminal repeat (LTR).
Transient transfections and CAT assays. A total of 5 3 105 C33a cells were
transfected with 2.5 mg of the respective CAT reporter plasmids together with 0.1
mg of a RSV LTR-driven luciferase construct as an internal reference, using a
lipofection protocol (Lipofectamine transfection kit; GIBCO, BRL). The cells
were treated with 100 mM PDTC as mentioned in the figure legends and har-
vested to determine the luciferase and CAT activity. Cellular extracts corre-
sponding to equal luciferase counts (16) were incubated for 1 to 2 h at 378C as
described by Gorman et al. (27).
EMSAs. For gel retardation tests, the following oligonucleotides were used:
AP-1-#3 of HPV-16 (59-ATAAAGGTTAGTCATACATTGTTC-39; positions
7804 to 7827) (12), the enhancer-specific AP-1 site of HPV-18 (59-CGCACCT
GGTATTAGTCATTTTCC-39; positions 7596 to 7620) (7), an AP-1 consensus
sequence (59-CGCTTGATGACTCAGCCGGAA-39) (38), and an Oct-1 consen-
sus oligonucleotide (59-TGTCGAATGCAAATCACTAGAA-39) (63). The
DNA was synthesized in an Applied Biosystems synthesizer using phosphoramit-
ide chemistry. For electrophoretic mobility shift assays (EMSAs), the annealed
oligonucleotides were labeled with [g-32P]ATP (3,000 Ci/mmol; Amersham) by
T4 polynucleotide kinase and gel purified from a 15% polyacrylamide gel (59).
Total cellular extracts were prepared as described by Dignam et al. (17). The
binding was performed in a 25-ml reaction volume containing 50% glycerol, 60
mM HEPES (pH 7.9), 20 mM Tris-HCl (pH 7.9), 300 mM KCl, 5 mM EDTA,
5 mM DTT, 100 mg of bovine serum albumin per ml, 2.5 mg of poly(dI-dC), and
5 mg of nuclear extract. After 5 min, 10,000 cpm of the [g-32P]ATP 59-end-
labeled double-stranded oligonucleotide probe was added, and the incubation
was continued for additional 25 min at room temperature.
For monitoring AP-1 composition in supershift assays, 2 mg of polyclonal
antibodies (Abs) directed against the Jun/Fos family (Santa Cruz Biotechnology)
was added, and the reaction mixtures was further incubated for 1 h at 48C. The
following Abs were used: c-Fos Ab (epitope corresponding to amino acids 3 to
16 mapping at the N terminus of human c-Fos protein), Fra-1 Ab (epitope
corresponding to amino acids 3 to 22 mapping at the N terminus of the human
Fra-1 protein), Fra-2 Ab (epitope corresponding to amino acids 3 to 22 mapping
at the N terminus of the human Fra-2 protein), and FosB Ab (epitope corre-
sponding to amino acids 102 to 117 of the mouse FosB protein). For the Jun
family, we used c-Jun Ab (epitope corresponding to amino acids 91 to 105
mapping within the amino-terminal domain of the mouse c-Jun protein), JunB
Ab (epitope corresponding to amino acids 45 to 61 mapping within the amino-
terminal domain of the mouse JunB protein), and JunD Ab (epitope correspond-
ing to amino acids 329 to 341 mapping within the carboxy terminus of mouse
JunD). The DNA-protein complexes were resolved on a 4.5% nondenaturing
polyacrylamide gel (29:1 cross-linking ratio), dried, and exposed overnight to
Kodak X-Omat films.
SDS-polyacrylamide gel electrophoresis and Western blotting. Cellular ex-
tracts used for the band shift analysis (15 mg of protein per lane) were separated
in sodium dodecyl sulfate (SDS)–12% polyacrylamide gels, electrotransferred to
Immobilon-P membranes (Millipore Corporation), and probed with polyclonal
rabbit antibodies of the corresponding Fos/Jun members (see above for details).
The incubation was carried out overnight in phosphate-buffered saline supple-
mented with 5% skim milk powder (Merck), 0.05% Tween 20 (Sigma), and a
1:5,000 dilution of the respective Ab. The bands were visualized with an anti-
rabbit immunoglobulin G antibody conjugated with horseradish peroxidase, us-
ing the Amersham ECL detection system.
Phosphatase treatment of the cellular extracts. To reduce the concentration of
NaCl present in the Dignam extract, 20 mg of cellular extract was 10-fold diluted
in 13 phosphatase buffer (50 mM Tris-HCl [pH 7.8], 2 mM MnCl2, 5 mM DTT,
100 mg of bovine serum albumin per ml) and treated with 400 U of l-phospha-
tase (New England Biolabs) for 30 min at 308C. As a control, the same extracts
were incubated under identical conditions without any enzyme. After acetone
precipitation, the phosphorylation status of c-Jun was monitored by Western
blotting with a monoclonal Ab specifically raised against c-Jun, phosphorylated
on serine 63 (epitope corresponding to amino acids 56 to 69) (Santa Cruz
Biotechnology).
DNA hybridization probes. pHPV16 and pHPV 18 represent unit-length of
HPV-16 (18) and HPV-18 DNA (6) cloned in pBR322. pHF-A1 (28), harboring
an approximately full-length insert of the fibroblast b-actin gene, was a generous
gift from L. Kedes (Medical Center, Palo Alto, Calif.). Plasmid pc-myc, contain-
ing the third exon of the human c-myc gene, was kindly made available by G.
Bornkamm (Institut fu¨r Klinische Molekularbiologie, Munich, Germany) (53).
The cDNAs for c-jun (2), c-fos (45), and theWAF gene (22) were kindly provided
by P. Angel (Deutsches Krebsforschungszentrum) and B. Vogelstein (John Hop-
kins University, Baltimore, Md.). The DNA harboring the human homolog for
the fra-1 gene (25) was a generous gift from M. Seiki (Cancer Research Institute,
Kanagawa, Japan). All probes were labeled by the random-priming technique
(23).
RESULTS
PDTC selectively suppresses HPV-16 transcription in hu-
man keratinocytes. Incubation of HPV-16-immortalized hu-
man keratinocytes (HPK Ia) (19) with the antioxidant PDTC
for 2 h reveals only a slight reduction of the virus-specific
mRNA steady-state level (Fig. 1A; compare lanes a and e).
However, HPV-16 gene expression becomes almost completely
down-regulated between 4 and 6 h (Fig. 1, lanes d and c) and
is no longer detectable after overnight treatment (16 h) (lane
b). With the half-life for the HPV-16-specific mRNA estimated
to be approximately 2.5 h (Fig. 1B, where the HPV 16 tran-
scripts decline between 120 and 240 min after actinomycin D
addition), PDTC interference seems to act at the level of
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initiation of transcription (see below), since the disappearance
of viral mRNA follows roughly the same kinetics as detected
with actinomycin D as a nonspecific transcriptional inhibitor
(Fig. 1B).
Accordingly, to demonstrate that PDTC-mediated HPV
suppression is a selective process and not the consequence of
a general transcriptional reduction, the RNA filter was rehy-
bridized with an endogenous reference gene such as c-myc or
the b-actin gene. Although a two- to threefold reduction of the
short-lived c-myc mRNA (13) can be noticed, the basic steady-
state level of the transcript remains constant and is almost
unaltered independent of incubation for 4 h (Fig. 1A, lane d)
or 16 h (lane b) in the presence of the drug. Furthermore,
subsequent hybridization with the human b-actin probe also
demonstrates that the suppression effect is virus specific (see
below) and not the result of a nonspecific transcriptional block
mediated by the antioxidant.
PDTC-mediated down-regulation of viral transcription is
transcriptionally regulated. To confirm the anticipation that
the suppression of HPV-16 is regulated at the level of initiation
of transcription, the elongation rates of nascent transcripts in
isolated HPK Ia nuclei were monitored by using the nuclear
run-on technique (39). Hybridization of identical counts of
[32P]UTP-labeled total RNA to defined amounts of DNA im-
mobilized on a membrane permits a direct correlation between
the degree of transcriptional activity at the HPV-16 integration
locus in comparison to other reference genes. With the inten-
sity of the hybridization signal of cellular DNA as an internal
standard, ongoing RNA synthesis of the b-actin gene is not
significantly altered (Fig. 2A). In contrast, the HPV-16-specific
signal is completely absent after 8 h of incubation in the pres-
ence of PDTC, which is in agreement with our previous acti-
nomycin D data (Fig. 1B), assuming that suppression of
HPV-16 is regulated at the level of initiation of transcription.
Moreover, to confirm that the PDTC-mediated down-regu-
lation of transcription is not a peculiarity of integrated HPV-16
FIG. 1. (A) Time-dependent down-regulation of HPV-16 transcription in the
presence of PDTC. HPV-16-immortalized human keratinocytes (HPK Ia) were
treated with PDTC for different periods of time. Lane a, untreated control; lanes
b to e, overnight and 6, 4, and 2 h of incubation in the presence of 100 mMPDTC,
respectively. The filter was consecutively hybridized with HPV-16, c-myc, and
b-actin probes. (B) Determination of the half-life of HPV-16 RNA. HPK Ia cells
were treated with 10 mg of actinomycin D per ml, and RNA was extracted 30, 60,
120, 240, and 300 min after drug addition. 2, RNA from untreated cells. The
filter was rehybridized with a b-actin probe. The positions of the 28S and 18S
rRNAs are indicated.
FIG. 2. (A) Nuclear run-on analysis of HPV-16 expression in HPK Ia. Equal
amounts of 32P-labeled nascent RNA were hybridized to nitrocellulose filters
carrying slots of 2.5 mg of linearized heat-denatured DNA of HPV-16, b-actin,
and an empty cloning vector as a negative control. As an internal positive control,
100 ng of total cellular DNA (cell.DNA) was applied. 2, untreated cells; 1,
hybridization with 32P-labeled RNA obtained from nuclei 8 h after treatment
with 100 mM PDTC. (B and C) Transient transfection assays of C33a cells, using
CAT reporter plasmids harboring the regulatory region of HPV-16 or HPV-18 or
the human topoisomerase I gene (TopoI). TRE and NFkB represent constructs
in which either three AP-1 consensus sequences from the collagenase promoter
(p3xAP-CAT) or three NF-kB consensus sites (p3xNF-kB CAT) were cloned in
front of the tk promoter of HSV (HSV tk). HSV tk is the basic cloning vector
pBLCAT2 (41) lacking any oligomerized sequences. 2 or 1 indicates either the
absence or the presence of 100 mM PDTC. Cells were cotransfected with 5 mg of
the corresponding CAT construct and 0.5 mg of an RSV LTR-driven luciferase
reporter plasmid, using the Lipofectamine transfection method. Extracts corre-
sponding to equal amounts of luciferase counts were incubated for 2 h at 378C to
perform the CAT reaction. The acetylated products were finally separated by
thin-layer chromatography. The locations of the [14C]chloramphenicol substrate
(CM) and the acetylated form (AC) are indicated.
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genomes but represents a more general phenomenon also act-
ing on episomal viral promoter elements, transient transfection
studies were performed. Since we noticed that PDTC was
unstable over prolonged periods of time, cell extracts were
prepared 16 h after transfection and assayed for luciferase
activity to correct the transfection efficiencies.
Examples of representative CAT assays are depicted in Fig.
2B and C. While PDTC treatment selectively reduces the tran-
scriptional activity of HPV-16, HPV-18, and simian virus 40
URR-driven reporter constructs, CAT activities of other ref-
erence promoters such as the tk promoter of HSV (41) or the
regulatory region of the human DNA topoisomerase I gene
(35) are not influenced under the same experimental condi-
tions. The negative interference of PDTC treatment with the
transcription factor NF-kB (67) was confirmed by using a
pBL2CAT construct harboring three copies of an NF-kB con-
sensus sequence in front of the HSV tk promoter as a positive
control (Fig. 2C). When the activity of a reporter construct
with triplicated TRE sequences upstream of the HSV tk pro-
moter is monitored, only a slight induction can be visualized
(Fig. 2C; see also below).
PDTC does not affecting p53 or the expression of the p53-
responsive gene WAF-1/p21. A recent study has shown that
HPV transcription can be down-regulated by p53, apparently
mediated through the epithelial cell-specific enhancer element
within the viral URR (15). Since the DNA-binding affinity and
biological activity of p53 can also be redox modulated under
certain circumstances (29), we examined the expression level
of the WAF-1/p21 gene, representing a known downstream
target for altered p53 activity (22).
If p53 activation is directly involved in viral gene suppres-
sion, one should expect that WAF/p21 is induced before any
E6/E7 down-regulation can be noticed. However, under con-
ditions where HPV-16 suppression can be discerned (Fig. 3;
compare lanes b and c), neither the p53 steady-state level itself
(57a) nor the expression of the cyclin-dependent kinase inhib-
itor WAF/p21 is significantly altered. This finding argues
against a direct involvement of p53 in the initial phase of
HPV-16 down-regulation during PDTC treatment. Whether
the lack of E6/E7 expression has some later downstream effects
on p53 or Rb activity remains to be clarified in further exper-
iments. Cross-hybridization with the cell cycle-regulated topo-
isomerase I gene (35) again shows no significant influence on
its transcriptional activity, which is in agreement with the re-
sults of previous experiments using the corresponding pro-
moter region in transient transfection assays (Fig. 2B).
AP-1 binding affinity in HPK Ia cells is up-regulated after
PDTC treatment. Since p53 seems to be not directly involved
in the PDTC-mediated suppression effect (Fig. 3), we focused
our attention on the transcription factor AP-1, whose binding
affinity to its cognate recognition site is also known to be
modulated by antioxidants (1, 44, 64). Extracts from PDTC-
treated and untreated HPK Ia cells were prepared and ana-
lyzed in band-shift assays either with a 32P-labeled probe har-
boring an AP-1 consensus sequence (38) (Fig. 4A) or with an
FIG. 3. Northern blot analysis of the p53-responsive WAF (p21) gene during
PDTC treatment in HPK Ia cells. Lane a, untreated control; lane b, RNA from
cells after 4 h of incubation; lane c, RNA obtained after 2 h of treatment in the
presence of 100 mM PDTC. The filter was hybridized first with HPV-16 DNA
and subsequently with a cDNA probe encoding the human topoisomerase I gene
(TopoI) and the cyclin-dependent kinase inhibitor p21 (WAF).
FIG. 4. EMSA using cellular extracts from untreated (2) and PDTC-treated (1) HPK Ia cells. Binding specificity was evidenced by preincubation with a 100-fold
molar addition of the homologous unlabeled oligonucleotide (lanes b and e in each panel) in comparison with competition experiments using a heterologous
oligonucleotide (lanes c and f in each panel). (A) EMSA with a 32P-labeled oligonucleotide harboring an AP-1 consensus sequence; (B) EMSA using a 32P-labeled
oligonucleotide containing the proximal AP-1 site (AP-1#3) of the HPV-16 URR; (C) EMSA carried out with a labeled oligonucleotide (oligo) encompassing the
consensus sequence of the Oct-1 transcription factor. The positions of the specific retarded bands are indicated. The squares mark the unspecific complexes.
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oligonucleotide encompassing the proximal HPV-16-specific
AP-1 recognition site of the viral regulatory region (AP-1#3,
positions 7811 to 7817) (12) (Fig. 4B). Although there also
exist two additional AP-1 sites within the HPV-16 URR (AP-
1#1 and AP-1#2, positions 7631 to 7638 and 7648 to 7655)
(12), we selected the proximal site for further investigations,
since AP-1#3 has the highest binding affinity and confers the
strongest trans-activating activity to heterologous promoters
when c-fos and c-jun expression vectors are used in transient
cotransfection assays (12).
Independently of whether a consensus binding site (Fig. 4A)
or a virus-specific AP-1 site (AP-1#3) is applied (Fig. 4B),
increased DNA binding affinity can be discerned (compare
lanes a and d in each panel). The binding is specific, since the
retarded complex disappears after competition with a 100-fold
molar excess of a homologous (Fig. 4A and B, lanes b and e)
but not with a heterologous probe, containing the consensus
sequence for the transcription factor Oct-1 (Fig. 4A and B,
lanes c and f). Furthermore, in agreement with previous re-
ports (44, 67), PDTC treatment selectively increases AP-1 but
not other transcription factors such as Oct-1 (Fig. 4C). Ele-
vated AP-1 binding was also obtained with HeLa cell extracts,
using an HPV-18-specific AP-1 oligonucleotide localized
within the constitutive enhancer region (positions 7596 to
7620) as well as with C33a cells lacking any known HPV type
(57a), which indicates that alteration in AP-1 binding by PDTC
is not exceptional for HPV-16-immortalized human keratino-
cytes but reflects a more general phenomenon independently
from the degree of malignancy.
PDTC influences the heterodimerization pattern of AP-1.
To understand the conceptual problem of how elevated levels
of a transcription factor, normally indispensable for efficient
HPV expression (7, 12, 77), could be involved in the suppres-
sion mechanism of viral transcription, AP-1 complexes were
dissected in their individual components in electromobility
band shift assays using specific Abs raised against the different
members of the Jun/Fos family.
While the c-Fos Ab fails to interact with AP-1 in untreated
HPK Ia cells (Fig. 5A, lane c), most of the signal is supershifted
after incubation with a c-Jun Ab (Fig. 5A, lane b). This finding
suggests that under normal conditions, there exists a certain
amount of AP-1 which mainly consists of c-Jun homodimers in
HPV-16-immortalized human keratinocytes.
On the other hand, when a c-Fos Ab is used, PDTC treat-
ment generates only faint supershift bands (Fig. 5A, lane f),
which presumably reflect heterodimerization products with
other members of the Jun family. Among those, only JunB
becomes increased (Fig. 5B, lanes c and g), while the binding
of JunD is not significantly altered (Fig. 5B, lanes d and h).
To determine whether inappropriate gene expression may
account for the absence of c-Fos within the AP-1 transcription
complex, RNA and protein analyses were performed. PDTC
incubation results in a strong increase of both c-Jun (Fig. 6A,
lanes b to d) and c-Fos (Fig. 6B, lanes b and c) transcription.
While the steady-state level of the c-jun mRNA is only slightly
reduced after overnight incubation (16 h) (compare lanes b
and d in Fig. 6A), c-fos transcription declines almost to the
basal level (Fig. 6B, lane d). In Western blot analyses, antiox-
idant treatment leads to a strong elevation of c-Jun and c-Fos
also at the protein level (Fig. 6C and D, lanes b and c). Hence,
inefficient gene expression cannot account for the underrepre-
sentation of c-Fos within the AP-1 complex.
Interestingly, PDTC seems also to trigger phosphorylation
of c-Jun, which is indicated by the slower-migrating band (51)
just in front of the c-Jun-specific signal (Fig. 6C). Treatment of
cellular extracts with l-phosphatase results not only in a dis-
appearance of this particular band but also in a reduction of
the c-Jun signal in general. Since the monoclonal Ab used here
is specifically raised against the phosphorylated N-terminal
part of c-Jun (epitope 56-69), signal reduction demonstrates
that obviously serine-63 is one of the major targets of the
PDTC effect (Fig. 6E; compare lanes a and b with lanes c and
d). Additionally, despite the fact that there is still detectable
c-fos mRNA 8 h after PDTC addition (Fig. 6B, lane c), the
protein becomes diminished (Fig. 6D; compare lanes b and c).
Whether this reflects differences in the metabolic turnover
rates of both proteins is presently not clear and awaits further
elucidation (see Discussion).
Additional experiments were carried out to detect further
variations in AP-1 composition after antioxidant treatment. As
demonstrated in supershift assays with Abs specific for mem-
bers of the Fos family, it became obvious that only Fra-1
predominantly heterodimerizes with c-Jun and JunB after
PDTC incubation (Fig. 7A, lane e). In parallel experiments in
which Fra-2 (compare lanes c and f) or FosB (57a) antibodies
were included, no supershifted protein-DNA complexes are
detectable. Monitoring the corresponding RNA (Fig. 7B) and
protein expression patterns (Fig. 7C), we found Fra-1 to be
FIG. 5. Electromobility supershift assays using 32P-labeled AP-1#3 oligonu-
cleotides. Extracts from untreated (2) and treated (1) HPK Ia cells were
incubated with specific Abs recognizing different members of the Fos/Jun family.
(A) Lanes a and d, without Ab; lanes b and e, addition of a c-Jun Ab; lanes c and
f, addition of a c-Fos Ab. (B) Lanes a, e, b and f, same as in panel A; lanes c and
g, JunB Ab addition; lanes d and h, incubation with a JunD Ab. The position of
the AP-1-specific complex is indicated. The arrowhead and the small arrows label
the supershifted bands after Ab addition. The squares mark the unspecific
complexes.
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elevated in both cases. Although the fra-1-specific mRNA is
also up-regulated, Fra-1 protein expression is not paralleled to
the same extend as demonstrated for c-Jun and c-Fos (Fig. 6).
Furthermore, the observation that c-Jun is already associated
with significant quantities of Fra-1 even in untreated cells (Fig.
7A, lane b) is intriguing, since the basal level of Fra-1 expres-
sion as well as its ratio in the AP-1 complex seem to be in-
versely correlated with the steady-state level of virus-specific
transcription (see Discussion).
DISCUSSION
During the past few years, it has become evident that there
exist a whole variety of transcription factors whose trans-acting
activity and DNA-binding affinity can be regulated by changes
of the intracellular redox status (for a review, see reference
68). Certain viruses such as human T-lymphotropic retrovirus
type 1 and Epstein-Barr virus use this strategy to induce pro-
liferation and growth advantage of their host cells (81). Infec-
tion by these viruses consistently leads to an elevation of thi-
oredoxin expression, which in turn protects the cells against
cytokine-dependent cytotoxicity by neutralizing intracellular
ROIs (42).
Another effective way to experimentally interfere with the
redox status of a eukaryotic cell is by use of antioxidative drugs.
PDTC is currently the agent best suited to modify the intra-
cellular redox status of a given gene under defined tissue cul-
ture conditions, having the advantage of a low toxicity and an
approximately 200-fold-higher efficiency than N-acetyl-L-cys-
teine to block NF-kB activity (67). PDTC can block not only
the transcription of endogenous cellular NF-kB-responsive
genes, such as the MCP-1 gene (57), but also the induction of
viral genes. For example, Tax-mediated NF-kB activation of
the LTR of human immunodeficiency virus type 1 is com-
pletely inhibited after use of micromolar concentrations of
PDTC for a brief period of time (66).
The other important transcription factor which is also mod-
ulated by this particular antioxidant is AP-1 (44, 64). AP-1 is
considered a central factor for tissue-specific transcription of
HPVs (49). To determine whether changes in the intracellular
redox status also influence HPV gene expression, we have
investigated the effect of PDTC on viral transcription by using
HPV-16-immortalized human keratinocytes (HPK Ia) (19) as
an in vitro model system.
In this study, we demonstrated that HPV-16 transcription
becomes selectively down-regulated upon PDTC treatment
with approximately the same kinetics as when actinomycin D is
used as a transcription inhibitor (Fig. 1). Nuclear run-on assays
confirm the anticipation that the absence of the viral mRNA is
not the result of a posttranscriptional control process as de-
scribed recently for some cytokine genes after application of
anti-inflammatory drugs (for a review, see reference 58) but
rather the consequence of a regulatory pathway acting at the
level of initiation of transcription (Fig. 2).
To gain a mechanistic insight into this effect, we first focused
on the function of the tumor suppressor protein p53. The
reasons why this particular protein was initially considered a
potential candidate for the negative regulatory effect on HPV
transcription can be summarized as followed. First, both the
conformation and the affinity to DNA are also redox regulated
through specific cysteine residues within the DNA-binding do-
main (29). p53 has to be in a reduced state for optimal binding
to DNA in a sequence-specific manner (54). Second, as re-
ported in a recent study, p53 overexpression alone is sufficient
to down-regulate HPV-16/18 transcription through the epithe-
lial cell-specific enhancer element within the viral URR (15).
Finally, the function of p53 is not irreversibly impaired through
the interaction with the E6 oncoprotein of HPV-16 or HPV-18
in cervical carcinoma cells (37, 62), since it can be reactivated
under certain experimental conditions, for instance, after UV
FIG. 7. Selective fra-1 induction after PDTC treatment. (A) Supershift assays
using 32P-labeled AP-1#3 oligoprobes. Extracts from untreated (2) and treated
(1) HPK Ia cells were incubated with a Fra-1- or Fra-2-specific Ab. Lanes a and
d; without Ab; lanes b and e, after addition of a Fra-1 Ab; lanes c and f, after
addition of a Fra-2 Ab. The arrowhead indicate the position of the complexes
supershifted after Ab addition; the squares mark the unspecific complexes. (B)
Northern blot analysis after hybridization with a fra-1-specific cDNA probe. The
positions of the 28S and 18S rRNAs are indicated. (C) Western blot analysis
using a Fra-1-specific antibody. Lanes a in panels B and C, untreated controls;
lanes b and c, PDTC treatment for 4 and 8 h, respectively.
FIG. 6. PDTC induces c-jun and c-fos expression in HPK Ia cells. (A and B)
Northern blot analysis after hybridization with jun/fos-specific cDNA probes. (A)
Lane a, untreated cells; lanes b to d, 16, 8, and 4 h of incubation with PDTC,
respectively. (B) Lane a, same as in panel A; lanes b to d, RNA from cells treated
for 4, 8, and 16 h with PDTC. The positions of the 28S and 18S rRNAs are
indicated. (C and D) Western blot analyses utilizing polyclonal c-Jun (C)- and
c-Fos (D)-specific antibodies. Lanes a, untreated control; lanes b and c, protein
extracts obtained from cells treated for 4 and 8 h with PDTC. (E) Lane a,
untreated control cells; lane b, 8-h PDTC treatment; lanes c and d, same as lanes
a and b but incubated with l-phosphatase for 30 min at 308C. (To compensate for
the signal reduction after l-phosphatase treatment, lanes c and d were exposed
approximately five times longer than the signals shown in lanes a and b.)
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irradiation (8). Functional reactivation of p53 can be easily
monitored by elevated expression of the cyclin-dependent ki-
nase inhibitor WAF/p21, which is a known target gene for p53
(22). Since WAF/p21 is not increased under conditions where
diminished HPV-16 mRNA can be discerned (Fig. 3), one can
exclude the possibility that p53 plays a significant role as a
potential effector during the down-regulation process of viral
transcription.
The finding that HPV-16 suppression is paralleled by an
increased AP-1 binding to its cognate binding site within the
viral regulatory region (Fig. 4) was initially unexpected, since
mutational analyses have demonstrated that AP-1 is not only
the major determinant for tissue specificity (49) but also abso-
lutely required for efficient viral gene expression (7, 12, 77).
To delineate this apparent paradox in molecular terms, EM-
SAs in combination with specific Abs raised against different
members of the Jun/Fos family were performed. As summa-
rized in Fig. 5, PDTC treatment triggers mainly the induction
of c-Jun binding (see also Fig. 6A and C), which represents the
major component of AP-1 in untreated HPK Ia cells (Fig. 5A
and B, compare lanes a and b). Although it has been reported
that JunB is predominantly found in human keratinocytes (77)
and sometimes even overexpressed in some cervical carcinoma
cells (10), the amount of JunB in uninduced cells is at least
10-fold lower than that of c-Jun (Fig. 5B, lanes b and c). The
weaker EMSA signal of JunB cannot be attributed to poorer
affinity to the corresponding AP-1 site, since c-Jun and JunB
have very similar DNA-binding properties (47). Western blot
analysis also confirms that c-Jun is more highly expressed than
JunB in our experimental system (57a). The c-Jun expression
pattern is obviously independent of the degree of malignancy,
because its level is reminiscent of that found in the cervical
cancer cell line HeLa (5) harboring another high-risk HPV
type, HPV-18.
Beside c-Jun binding, JunB binding at the proximal HPV-16
AP-1 site is also elevated upon antioxidant treatment (Fig. 5B,
lane g). This is intriguing in the context of the observed sup-
pression effect, since there exists an inverse relationship be-
tween JunB expression and the efficiency of c-Jun homodimers
or c-Jun/c-Fos heterodimers to trans-activate AP-1-responsive
indicator genes (11, 69). In contrast to JunB, JunD is not
affected under the same conditions (Fig. 5B; compare lanes d
and h).
PDTC induces not only c-Jun and to a certain extend JunB
expression but also c-Fos expression both at the RNA and
protein levels (Fig. 6B and D). However, in contrast to the
HeLa cell system, where transcription of these genes reaches a
peak after 60 min and declines to the baseline level after 90
min (44), both genes remain expressed even 8 h after PDTC
application (Fig. 6A and D). Remarkably, monitoring of the
composition of AP-1 in the band shift assay showed that c-Fos
did not participate in the AP-1 transcription complex forma-
tion, since supershifted bands were only barely detectable (Fig.
5A, lane f). Instead, as shown in Fig. 7A (lanes b and e), c-Jun
and JunB mainly become associated with Fra-1, which is the
only member of the Fos family found to be elevated during
PDTC treatment (Fig. 7B and C).
Changes of AP-1 composition by antioxidants is not without
a precedent. A recent study has demonstrated that the phe-
nolic antioxidant tert-butylhydroquinone antagonizes the tran-
scriptional effects of AP-1 during treatment with the tumor
promoter 12-O-tetradecanoylphorbol-13-acetate by preferen-
tial formation of c-Jun/Fra-1 heterodimers (83). Additionally,
Fra-1 can efficiently negatively interfere with c-Jun and c-Fos
in activating AP-1-responsive indicator genes (75). Hence, in
addition to JunB, Fra-1 seems to be an essential key element in
neutralizing the function of AP-1, known to be obligatory for
initiation and maintenance of viral transcription at the URR of
HPV-16 or HPV-18 (7, 12, 77). However, suppression of viral
transcription obviously requires both a balanced stoichiometry
of a defined set of AP-1 components and their posttransla-
tional modification (e.g., c-Jun phosphorylation [see below]),
since the mere overexpression of AP-1 components by effector
plasmids failed to suppress HPV-16/18 URR-driven reporter
constructs in transient transfection assays (57a). Stable intro-
duction of a fra-1 cDNA by using inducible expression systems
may be an alternative approach to address such questions. On
the other hand, besides HPV, c-myc (Fig. 1A, lanes b to d)
seems to be another gene whose activity is reduced due to
alterations of the AP-1 heterodimerization pattern. Analysis of
the corresponding regulatory region has revealed that there
exists an AP-1 binding site within a negative element of the P1
promoter, which is involved in the transcriptional modulation
of this particular cellular proto-oncogene (76).
Furthermore, it is should be noted that the fra-1 gene is
localized in a chromosomal region (11q13) (71) which is often
structurally affected in cervical carcinoma cells (32). This could
be of particular relevance with respect to the tumor-suppress-
ing function of chromosome 11 (34, 61) and the different pat-
terns of regulation of HPV transcription in malignant and
nonmalignant cells (55, 56, 85). In fact, preliminary experi-
ments using somatic cell hybrids between tumorigenic HeLa
cells and normal human fibroblasts (73) reveal the occurrence
of a higher ratio of Fra-1 within the AP-1 transcription com-
plex in nontumorigenic hybrid cells than in tumorigenic seg-
regants or in parental HeLa cells (57a), both lacking the nor-
mal allele of chromosome 11 (72). Interestingly, tumor
necrosis alpha treatment, which selectively suppresses HPV-18
transcription in nontumorigenic hybrids (57), makes this effect
more pronounced. It remains to be seen whether there is a
causal relationship between cytokine- and PDTC-mediated
down-regulation of viral gene expression. The finding that di-
thiocarbamates induce cytokine release in human bone mar-
row cells (21) could support the suggestion of a potential link
between the two phenomena.
Another important problem concerns c-Fos, which is
strongly induced by PDTC at both the RNA and protein levels
(Fig. 6B and D). Although complex formation is a very dy-
namic process consisting of defined association and dissocia-
tion events, c-Fos does not become heterodimerized with c-Jun
and JunB (Fig. 5A, lane f). Since c-Jun is phosphorylated upon
PDTC treatment (Fig. 6C and E), it is tempting to speculate
that apart from simple competition with Fra-1 in heterodimer-
ization, posttranslational modification of c-Jun may account
for the exclusion of c-Fos from AP-1 complex formation. In-
deed, there is accumulating evidence that the metabolic stabil-
ity of c-Fos is regulated by c-Jun phosphorylation (50, 79). The
targeted degradation of c-Fos is catalyzed by the 26S protea-
some in an ubiquitin-dependent pathway, which is accelerated
when phosphorylated c-Jun is present (79). Which kinds of
protein kinases are involved in this process is currently under
investigation.
Although c-Fos is underrepresented in the AP-1 transcrip-
tion complex (Fig. 5A, lane f), it should be stressed that AP-1
activity is not completely neutralized. Consistent with this no-
tion is the induction of c-jun transcription by PDTC (Fig. 6A),
known to be autoregulated by its own gene product (3). Ad-
ditionally, transient transfection assays with reporter con-
structs harboring tandem repeats of AP-1 sites in front of the
HSV tk promoter are still trans activated after PDTC addition
(44) (Fig. 2). The low but nevertheless inducible amount of
c-Fos is obviously sufficient for proper AP-1 function, since
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c-Jun/c-Fos heterodimers, albeit underrepresented (Fig. 5A),
have a higher stability and a more effective trans-acting activity
than Jun-Jun homodimers alone (for a review, see reference
4). Moreover, activation of AP-1 indicator plasmids after
PDTC treatment is also in good agreement with our finding of
higher JunB binding (Fig. 5B, lane g), because JunB is a better
activator of promoters containing multimerized AP-1 sites.
Promoters with only one AP-1 site were not trans activated
(10). This finding in turn stresses the importance of the num-
ber and the locations of AP-1 sites in their natural context
within a particular promoter (4, 10), an observation which is
probably also true for the viral regulatory regions investigated
here in this study.
Since AP-1 is a common and indispensable key regulator for
tissue specificity and transcriptional activity for various HPV
types (12, 36, 49), antioxidant-induced modification of such an
important transcription factor is obviously sufficient to inter-
fere with the architecture of an HPV-specific transcription
complex, resulting in a selective suppression viral gene expres-
sion. How AP-1 is neutralized and by which mechanism mod-
ified AP-1 can disturb the interplay with other virus-specific
factors during transcriptional initiation remain to be eluci-
dated. Nevertheless, since dithiocarbamates have been phar-
macologically evaluated in animal experiments (24), our study
may provide a basis for a novel therapeutic approach to effi-
ciently interfere with the expression of pathogenic HPVs by
using antioxidative drugs such as PDTC.
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